Supply Status of Emerade Adrenaline Auto-Injectors - Statement from Bausch + Lomb in the UK
Bausch + Lomb is committed to helping ensure that patients have access to the medicines they need, and we are working diligently to help supply the market with this critical medicine. Over the last year we have seen a large increase in demand for our products due to supply issues with other Adrenaline Auto-injectors (AAIs) and we have worked very closely with our manufacturing partners to substantially increase production across our range of Emerade 150mcg, 300mcg and 500mcg Adrenaline Auto-Injectors to help support patients.
Emerade 500mcg (Adrenaline Tartrate)
Further volumes of Emerade 500mcg (Adrenaline Tartrate) will be available in wholesalers from 18th of October and we are working with our supply chain to ensure that this is optimized to be available to patients with a valid Emerade 500mcg prescription. The next shipment will be available in November.
Emerade 300mcg (Adrenaline Tartrate)
Further supply of Emerade 300mcg (Adrenaline tartrate) will be available in wholesalers on the 18th of October, and we are working with our supply chain to ensure that this is optimized to be available to patients with a valid Emerade 300mcg prescription. The next shipment will be available in November.
Emerade 150mcg (Adrenaline Tartrate)
There is an additional supply of Emerade 150mcg (primarily a paediatric dose) which should be available in pharmacy and wholesalers on Monday 14th of October.
Bausch + Lomb advise that patients should seek advice from your Health Care Practitioner